• Anthony G B Walters and Geoffrey Braatvedt.
• Department of Endocrinology, Auckland City Hospital, Auckland, New Zealand.
• Intern Med J. 2021 Jul 1; 51 (7): 1016-1020.

AbstractImmune checkpoint inhibitors are increasingly being utilised as an effective therapy for a variety of cancers. However, they have the potential to cause serious autoimmune toxicities in multiple organ systems termed 'immunotherapy-related adverse events'. Endocrine toxicities are common, can occur well after commencement of therapy and can result in significant morbidity and mortality if not recognised. This makes it important for all physicians, in addition to endocrinologists and oncologists, to understand the nature of these reactions and the general approach to their diagnosis and management. This review aims to provide an overview of the epidemiology, pathophysiology, clinical presentation and management of the endocrine adverse events.© 2020 Royal Australasian College of Physicians.

15 keywords...

hide…